(Q35211226)

7 August 2017

1 reference

title

A major health hazard: the metabolic syndrome (English)

1 reference

7 August 2017

1 reference

Bo Isomaa

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

7 August 2017

number of pages

17

1 reference

based on heuristic

inferred from page(s)

published in

Life Sciences

1 reference

7 August 2017

volume

73

1 reference

7 August 2017

issue

19

1 reference

7 August 2017

page(s)

2395-2411

1 reference

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Comment on the provisional report from the WHO consultation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Social inequality in coronary risk: Central obesity and the metabolic syndrome. Evidence from the Whitehall II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Chronic activation of the innate immune system may underlie the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Catch-up growth in childhood and death from coronary heart disease: longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

How to measure insulin sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

A comparison of the prevalence of the metabolic syndrome using two proposed definitions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Heritability of albumin excretion rate in families of patients with Type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

The dysmetabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Fetal and infant growth and impaired glucose tolerance at age 64.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Components of the "metabolic syndrome" and incidence of type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Stress and the metabolic syndrome: an interesting but enigmatic association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Cardiovascular morbidity and mortality associated with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Genetic and environmental factors in relative body weight and human adiposity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Association of nonalcoholic fatty liver disease with insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Genetics of insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Elevated serum uric acid--a facet of hyperinsulinaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Endothelial dysfunction in human diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

New evidence for beneficial effects of statins unrelated to lipid lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Physical consequences of schizophrenia and its treatment: the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Dissecting the genetic architecture of lipids, lipoproteins, and apolipoproteins: lessons from twin studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Low density lipoprotein oxidation and its pathobiological significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Adverse endothelial function and the insulin resistance syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Endothelial dysfunction in men with small LDL particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Birthweight and adult health outcomes in a biethnic population in the USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

The assessment of insulin resistance in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Education and the metabolic syndrome in women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Physical fitness and clustering of risk factors associated with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Global and societal implications of the diabetes epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

Addressing the insulin resistance syndrome: a role for the thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2803%2900646-5

10.1016/S0024-3205(03)00646-5

7 January 2021

Identifiers

DOI

1 reference

7 August 2017

1 reference